华兰生物：重组Exendin-4-Fc融合蛋白注射液获准开展临试

Core Viewpoint - The company Hualan Biological (002007.SZ) has received approval from the National Medical Products Administration for clinical trials of a new drug, HL08, which is aimed at improving weight control in obese patients in addition to its original indication for type 2 diabetes management [1] Group 1 - The drug HL08 is a recombinant Exendin-4-Fc fusion protein injection [1] - The original indication for HL08 was to improve blood glucose control in patients with type 2 diabetes [1] - The newly approved indication expands its use to include weight control in obese patients [1]